A New Perspective on The Aduhelm Controversy
In June, the FDA granted “accelerated approval” to Biogen’s Aduhelm drug. This is the first…
Rigsby RigsbyOctober 15, 2021
Research in Down syndrome Associated Alzheimer’s disease: What do we know and where are we going?
In this webinar, Dr. Hendrix will discuss this important milestone in Alzheimer’s disease research and…
Biogen Announces New Hope for Alzheimer’s Drug Candidate Aducanumab
On October 22, 2019, the biopharmaceutical company, Biogen, announced that they will be going to…
Capetivate capetivateJuly 14, 2020